Alzheimer’s Clinical Trials for Seniors

Our extensive experience in Alzheimer’s clinical trials for seniors, combined with our relationships with leading universities and pharmaceutical companies, supports the advancement of early detection, the slowing of disease progress and our quest to end Alzheimer’s disease.

Research partners include Harvard University, Johns Hopkins University, University of Southern California, Eli Lilly, Eisai, Biogen and many others.

Our Alzheimer’s clinical trials for seniors employ the latest methodologies and are based on the most encouraging theories. By joining other participants, you are helping develop medical treatments as well as breakthrough technologies.

We cover participants’ clinical trial costs, offer access to our other memory care programs and, in some cases, compensation may be available for time and travel.

If you are interested in participating or learning more about our Alzheimer’s clinical trials for seniors, please call 305.514.8710 or email clinicaltrials@miamijewishhealth.org

 


 

CURRENT CLINICAL TRIALS

A study to assess the safety, tolerability, and efficacy of Donanemab in early symptomatic Alzheimer’s disease

  • Name of Study: I5T-MC-AACI
  • Description of Study: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
  • Indication: Early Symptomatic Alzheimer’s Disease
  • Recruiting Participant Age: 60 – 85 years of age
  • Duration of Study: 2 years

 

A study to assess the efficacy and safety of JNJ-63733657 in participants with early Alzheimer’s disease

  • Name of Study: Janssen Research & Development 63733657ALZ2002
  • Description of Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease
  • Indication: Early Alzheimer’s Diseases
  • Recruiting Participant Age: 55 – 80 years of age
  • Duration of Study: 2 years

 

A study to evaluate the efficacy and safety of  Seltorexant in adult and elderly patients with major depressive disorder with insomnia symptoms who have responded inadequately to antidepressant therapy

  • Name of Study: Janssen Research & Development 42847922MDD3005
  • Description of Study: This is a Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of  Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
  • Indication: Adult and elderly patients with Major Depressive Disorder with insomnia symptoms who have responded inadequately to antidepressant therapy.
  • Recruiting Participant Age: 18 – 74 years of age
  • Duration of Study: 2 years

 

An evaluation of the safety and tolerability of sage-718 in participants with mild cognitive impairment or mild dementia due to alzheimer’s disease

  • Name of Study: Sage 718-CNA-201
  • Description of Study: An Open-Label Evaluation Of The Safety And Tolerability Of Sage-718 In Participants With Mild Cognitive Impairment Or Mild Dementia Due To Alzheimer’s Disease
  • Indication: Mild Cognitive Impairment or Mild Dementia Due To Alzheimer’s Disease
  • Recruiting Participant Age:  50 – 80 years of age
  • Duration of Study: 2 years

 

Long-Term Nicotine Treatment of Mild Cognitive Impairment

  • Name of Study: MIND Study – Long-Term Nicotine Treatment of Mild Cognitive Impairment. Academia Study, funded by the National Institute on Aging (NIA) and conducted by Vanderbilt University and University of Southern California
  • Description of Study: The purpose of the Memory Improvement through Nicotine Dosing (MIND) Phase II study is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with MCI.
  • Indication: Mild Cognitive Impairment or Memory Loss
  • Recruiting Participant Age: 55+ years
  • Duration of Study: 2 years

 

Clinical trial of Dronabinol in Nursing Home patients with severe agitation

  • Name of Study: Dronabinol – Johns Hopkins
  • Description of Study: This is a Phase II placebo-controlled, double-blind randomized clinical trial of Dronabinol in Nursing Home patients with severe agitation – AD.
  • Indication: Alzheimer’s Disease with Agitation
  • Recruiting Participant Age:  18+ years
  • Duration of Study: Approximately 24 weeks (12-week treatment period)

 

An assessment of the safety, tolerability and efficacy of Escitalopram for Agitation in Alzheimer’s Disease

  • Name of Study: S-CitAD – Johns Hopkins
  • Description of Study: This is a Phase II placebo-controlled, masked study, assessing the safety, tolerability and efficacy of Escitalopram for Agitation in Alzheimer’s Disease.
  • Indication: Alzheimer’s Disease with Agitation
  • Recruiting Participant Age: 18 years +
  • Duration of Study: Approximately 24 weeks (12-week treatment period)

 

An assessment of the safety and efficacy of T3D-959 in subjects with Mild to Moderate Alzheimer’s Disease

  • Name of Study: T3D Therapeutics – T3D959
  • Description of Study: This is a Phase II placebo-controlled, double–blind randomized study, assessing the safety and efficacy of T3D-959 in subjects with Mild to Moderate Alzheimer’s Disease.
  • Indication: Mild to Moderate Alzheimer’s Disease
  • Recruiting Participant Age: 50 – 90 years of age
  • Duration of Study: Approximately 24 weeks

 

An evaluation of the efficacy and safety of AGB101 (low-dose levetiracetam) in subjects with Early Alzheimer’s Disease.

  • Name of Study: Agene Bio – AGB101 MCD
  • Description of Study: This is a Phase III placebo-controlled, double-blind study, evaluating the efficacy and safety of AGB101 (low-dose levetiracetam) in subjects with Early Alzheimer’s Disease.
  • Indication: Meets criteria for Mild Cognitive Impairment (MCI) – Mild Alzheimer’s Disease
  • Recruiting Participant Age: 55 – 85 years of age
  • Duration of Study: 18 months

Live Life Better

Contact Us Today